PriceTargets.com logo

Esperion Therapeutics - ESPR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.30
  • Forecasted Upside: 233.33%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.19 As of 12/20/2024 06:51 PM ET
▲ +0.02 (0.92%)

This chart shows the closing price for ESPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Esperion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESPR

Analyst Price Target is $7.30
▲ +233.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $7.30, with a high forecast of $16.00 and a low forecast of $2.50. The average price target represents a 233.33% upside from the last price of $2.19.

This chart shows the closing price for ESPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Esperion Therapeutics. This rating has held steady since February 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024The Goldman Sachs GroupInitiated CoverageNeutral$4.00
12/17/2024Cantor FitzgeraldInitiated CoverageOverweight$8.00
12/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
12/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
8/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$8.00 ➝ $6.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
6/20/2024Bank of AmericaDowngradeNeutral ➝ Underperform$2.90 ➝ $2.50
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00
3/25/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
2/28/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $16.00
2/27/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
1/3/2024Bank of AmericaDowngradeBuy ➝ Neutral
11/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$22.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$9.00 ➝ $8.00
10/2/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$9.00
8/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$22.00
8/2/2023Needham & Company LLCLower TargetBuy ➝ Buy$10.00 ➝ $9.00
8/1/2023Northland SecuritiesUpgradeUnder Perform ➝ Market Perform
6/15/2023Bank of AmericaUpgradeUnderperform ➝ Buy$1.25 ➝ $4.00
3/28/2023Needham & Company LLCReiterated RatingBuy$12.00
3/16/2023HC WainwrightReiterated RatingBuy$22.00
3/16/2023Needham & Company LLCLower TargetBuy$16.00 ➝ $12.00
3/16/2023Northland SecuritiesDowngradeMarket Perform ➝ Under Perform
3/16/2023Bank of AmericaDowngradeNeutral ➝ Underperform$8.00 ➝ $1.50
3/7/2023Credit Suisse GroupUpgradeUnderperform ➝ Neutral$6.50 ➝ $7.00
3/6/2023HC WainwrightReiterated RatingBuy$22.00
3/6/2023Needham & Company LLCBoost TargetBuy$12.00 ➝ $16.00
3/6/2023JMP SecuritiesReiterated RatingMarket Outperform$15.00
2/27/2023JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $9.00
2/27/2023Bank of AmericaInitiated CoverageNeutral ➝ Neutral$8.00
2/24/2023Jefferies Financial GroupUpgradeHold ➝ Buy$12.00
2/22/2023Needham & Company LLCReiterated RatingBuy$12.00
2/3/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$9.00
11/2/2022Morgan StanleyBoost TargetUnderweight$7.00 ➝ $9.00
8/9/2022CowenLower Target$13.00
8/3/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform$7.00 ➝ $6.00
7/15/2022Morgan StanleyBoost TargetUnderweight$5.00 ➝ $7.00
5/4/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$6.00
3/10/2022HC WainwrightInitiated CoverageBuy$22.00
1/14/2022Credit Suisse GroupLower TargetNeutral$8.00 ➝ $6.00
1/12/2022Northland SecuritiesLower Target$10.00 ➝ $5.00
12/9/2021Needham & Company LLCLower TargetBuy$20.00 ➝ $12.00
12/6/2021Credit Suisse GroupLower TargetNeutral$11.00 ➝ $8.00
10/19/2021CowenLower TargetPositive ➝ Outperform$60.00 ➝ $30.00
10/18/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$28.00 ➝ $11.00
10/14/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$17.00 ➝ $11.00
9/22/2021The Goldman Sachs GroupLower TargetSell$16.00 ➝ $8.00
9/14/2021JMP SecuritiesReiterated RatingBuy$90.00
8/4/2021Morgan StanleyLower TargetEqual Weight$22.00 ➝ $17.00
8/3/2021Needham & Company LLCLower TargetStrong-Buy$134.00 ➝ $114.00
5/11/2021Stifel NicolausReiterated RatingBuy ➝ Hold$37.00 ➝ $20.00
5/5/2021BTIG ResearchLower Target$90.00 ➝ $71.00
5/5/2021Northland SecuritiesLower TargetMarket Perform$30.00 ➝ $24.00
5/5/2021Credit Suisse GroupLower TargetOutperform$45.00 ➝ $36.00
5/5/2021Morgan StanleyLower TargetEqual Weight$30.00 ➝ $22.00
5/5/2021JMP SecuritiesLower TargetMarket Outperform$191.00 ➝ $111.00
5/5/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $20.00
3/11/2021Morgan StanleyInitiated CoverageEqual Weight$30.00
2/25/2021Needham & Company LLCLower TargetStrong-Buy$150.00 ➝ $134.00
2/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $30.00
2/9/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$44.00 ➝ $24.00
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$52.00 ➝ $35.00
11/10/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00
10/15/2020Bank of AmericaLower TargetBuy$55.00 ➝ $52.00
9/29/2020JPMorgan Chase & Co.Initiated CoverageSell$35.00
8/17/2020Bank of AmericaLower TargetBuy$60.00 ➝ $55.00
8/11/2020Needham & Company LLCReiterated RatingBuy$158.00
8/10/2020Stifel NicolausReiterated RatingBuy$75.00
8/10/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$83.00 ➝ $45.00
6/29/2020Credit Suisse GroupInitiated CoverageBuy$83.00
6/26/2020Stifel NicolausReiterated RatingBuy$75.00
6/23/2020Northland SecuritiesInitiated CoverageHold$42.00
6/9/2020Credit Suisse GroupReiterated RatingBuy$87.00
5/7/2020Jefferies Financial GroupLower TargetBuy$85.00 ➝ $70.00
5/7/2020Needham & Company LLCReiterated RatingBuy
5/7/2020Northland SecuritiesReiterated RatingHold$42.00
5/7/2020CitigroupBoost TargetBuy$46.00 ➝ $56.00
5/6/2020Stifel NicolausReiterated RatingBuy$76.00
4/20/2020Stifel NicolausReiterated RatingBuy
4/20/2020Needham & Company LLCReiterated RatingBuy$158.00
4/16/2020Northland SecuritiesLower TargetMarket Perform$60.00 ➝ $42.00
4/6/2020Needham & Company LLCReiterated RatingBuy$158.00
4/1/2020Bank of AmericaInitiated CoverageBuy$50.00
3/31/2020Needham & Company LLCReiterated RatingBuy$158.00
3/17/2020CitigroupUpgradeNeutral ➝ Buy
2/28/2020JPMorgan Chase & Co.Boost TargetNeutral$46.00 ➝ $47.00
2/27/2020CowenReiterated RatingBuy$87.00
2/24/2020Needham & Company LLCBoost TargetStrong-Buy$144.00 ➝ $158.00
2/24/2020JMP SecuritiesReiterated RatingOutperform$191.00
2/23/2020Stifel NicolausReiterated RatingBuy$83.00
2/23/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$60.00
2/19/2020BTIG ResearchReiterated RatingBuy$90.00
2/14/2020CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $82.00
1/31/2020Chardan CapitalReiterated RatingHold$65.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 11 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 12 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 12 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Esperion Therapeutics logo
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $2.19
Low: $2.12
High: $2.23

50 Day Range

MA: $2.42
Low: $2.00
High: $3.83

52 Week Range

Now: $2.19
Low: $1.58
High: $3.94

Volume

6,135,917 shs

Average Volume

6,377,633 shs

Market Capitalization

$431.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $7.30, suggesting a possible upside of 233.3%. HC Wainwright has the highest price target set, predicting ESPR will reach $16.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $2.50 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

Other companies that are similar to Esperion Therapeutics include Galapagos, Xencor, Evotec, Arcutis Biotherapeutics and Nurix Therapeutics. Learn More about companies similar to Esperion Therapeutics.

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is (734) 887-3903 and its investor relations email address is [email protected]. The official website for Esperion Therapeutics is www.esperion.com. Learn More about contacing Esperion Therapeutics investor relations.